Prosecution Under Drugs & Cosmetics Act Barred If Complaint Filed Beyond 3-Year Limitation Period From Date of Analyst Report: Supreme Court - 2025-07-29

Legal News & Court Updates.

SC Quashes Proceedings Against Pharma Directors, Cites Inexcusable Delay by Drug Inspector

New Delhi: The Supreme Court has quashed criminal proceedings against the directors of a pharmaceutical company, ruling that the prosecution was barred by the statute of limitations. Emphasizing the legal maxim that "law helps the vigilant, not the indolent," the Court held that the three-year limitation period for filing a complaint under the Drugs and Cosmetics Act, 1940, commences from the date the government analyst's report is received, and administrative delays in gathering information cannot be used to extend this period.

Case Background: A Delayed Prosecution

The case originated in January 2010 when a Drug Inspector in Kozhikode, Kerala, collected samples of Rabeprazole tablets manufactured by Indica Laboratories (Pvt.) Ltd. Subsequent laboratory analysis reports, received on March 30, 2010, and April 9, 2010, concluded that the drug was "not of standard quality."

However, the Drug Inspector filed complaints against the company's directors only on June 24, 2013, and July 3, 2013—more than three years after receiving the incriminating reports. The directors were charged under Section 18 (a)(i) read with Section 27 (d) of the Drugs and Cosmetics Act, 1940, for distributing a sub-standard drug.

The Core Legal Question: When Does the Clock Start Ticking?

The central issue before the Supreme Court was whether the complaints were filed within the three-year limitation period prescribed by Section 468 (2)(c) of the Code of Criminal Procedure (CrPC).

The appellants (the company directors) argued that the prosecution was time-barred as the complaints were filed well after the three-year window had closed. The respondent (the Drug Inspector) contended, and both the Trial Court and the Kerala High Court agreed, that the time taken to send prosecution notices and collect details of the accused should be excluded, bringing the complaints within the limitation period.

Supreme Court's Analysis: No Room for Indolence

The Supreme Court decisively overturned the lower courts' findings, holding their reasoning to be "unsustainable in the eyes of law." The bench clarified the application of the limitation law in such cases:

• Commencement of Limitation: The Court established that for an offence under the Drugs and Cosmetics Act, 1940, the "date of the offence" under Section 469(a) of the CrPC is the date on which the drug analyst's report is received. In this case, the limitation period began on March 30, 2010, and April 9, 2010.
• Deadline for Complaint: Consequently, the complaints should have been filed by March and April 2013, respectively. The actual filing in June and July 2013 was clearly beyond the statutory time limit.

Pivotal Court Observations

The judgment sharply criticized the justification for the delay, noting that the prosecutor's claims of needing time to gather company details were unfounded. The Court pointed out a crucial piece of evidence:

> "The evidence on record clearly states that the requisites such as the details of the manufacturing company required for initiating proceedings under the 1940 Act are present in the Government Analyst Report in Form-13 which was received by the respondent on the above-mentioned dates... Therefore, it cannot be denied that the complainants were well aware about the particulars of the company from the very beginning."

The Court further observed that the complainant had never formally requested a condonation of the delay, and the lower courts had "exceeded their power in awarding a benefit that was never claimed by the respondents."

Reinforcing the principle of timely justice, the bench stated:

> "The spirit of the law on limitation lies in the maxim vigilantibus non dormientibus jura subveniunt . Law helps the vigilant, not the indolent."

Final Verdict and Implications

Finding that the proceedings were unequivocally barred by limitation, the Supreme Court allowed the appeals and quashed the impugned judgment of the High Court, thereby terminating the criminal cases against the directors of Indica Laboratories.

This ruling serves as a significant precedent, clarifying that the limitation period in drug quality cases is strict and begins from the receipt of the analyst's report. It sends a strong message to prosecuting agencies that administrative inefficiency is not a valid excuse for delaying legal action beyond the period prescribed by law.